Clinical trials: Metastasis Colorectal Cancer
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Colorectal Cancer
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
- Trial name
- NCT00111761
- Testing
- Irinotecan, Panitumumab, 5-Fluorouracil
- Volunteers
- 43 people
- Sponsor
- Amgen
Advanced Cancer, Metastatic Cancer
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02860780
- Testing
- prexasertib, ralimetinib
- Where
- 3 sites in United States, Germany
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal…
- Trial name
- HORIZON I (NCT00278889)
- Testing
- AZD2171, 5-fluorouracil, Leucovorin
- Where
- 43 sites in Austria, Belgium and 7 more
- Volunteers
- 215 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
- Trial name
- NCT05368805
- Testing
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Colorectal Carcinoma
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have…
- Trial name
- NCT00362102
- Testing
- Cetuximab
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Metastatic Colorectal Cancer
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an…
- Trial name
- NCT07549412
- Testing
- Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI)
- Where
- 92 sites in United States, Argentina and 16 more
- Volunteers
- 1,020 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by…
- Trial name
- Keynote-559 (NCT03168139)
- Testing
- Olaptesed pegol - Monotherapy, Olaptesed pegol + Pembrolizumab - Combination Therapy
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- TME Pharma AG
Colorectal Cancer Metastatic
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.
- Trial name
- NCT05584137
- Testing
- HLX26, HLX10
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Liver Resection, Colorectal Carcinoma Liver Metastases
Safety of HRX215 in Patients After Minor and Major Liver Resection
The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1.
- Trial name
- NCT06638502
- Testing
- HRX215 capsules
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 80 people
- Sponsor
- HepaRegeniX GmbH
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Metastatic Colorectal Cancer (mCRC)
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and…
- Trial name
- NCT07391566
- Testing
- LPM6690176, Bevacizumab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Luye Pharma Group Ltd.
Colorectal Cancer, Metastases
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options…
- Trial name
- NCT00113763
- Testing
- Best supportive care, Panitumumab
- Volunteers
- 463 people
- Sponsor
- Amgen
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479…
- Trial name
- NCT01562899
- Testing
- MEK162, AMG 479
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.